Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121907 | 0.92 | NOS3 (0.56) | OPRM1NOS3NOS1CHRNB4CHRNA3 | |
| SCHEMBL2263047 | 0.87 | OPRM1 (0.58) | OPRM1NOS3NOS1CHRNB4CHRNA3 | |
| SCHEMBL12367467 | 0.83 | NOS3 (0.56) | OPRM1NOS3NOS1CHRNB2CHRNA4 | |
| SCHEMBL2264780 | 0.83 | OPRM1 (0.54) | OPRM1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL12608623 | 0.78 | OPRM1 (0.55) | OPRM1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2125182 | 0.78 | KMT2A (0.53) | CNR1CNR2CYP19A1 | |
| SCHEMBL1122698 | 0.77 | NOS3 (0.63) | NOS3NOS1CHRNB2CHRNA4CHRM3 | |
| SCHEMBL2266718 | 0.75 | CHRNB4 (0.50) | OPRM1NOS3NOS1CHRNB4CHRNA3 | |
| SCHEMBL12608698 | 0.74 | OPRM1 (0.51) | OPRM1CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL2267374 | 0.73 | OPRM1 (0.47) | OPRM1CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010527-B1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2013-08-14 | — | — | EP | disclosed |
| CN-101466709-B | 1,5 and 3, 6-substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2013-03-20 | — | — | CN | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| CN-101466709-A | 1, 5 and 3, 6-substituted indole compounds having NOS inhibitory activity | NEURAXON INC (CA) | 2009-06-24 | — | — | CN | disclosed |
| EP-2010527-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2009-01-07 | — | — | EP | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| WO-2007118314-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | OPRM1 157/4885NOS3 2/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.